Genofocus Stock Net Asset

187420 Stock   4,050  165.00  3.91%   
GenoFocus fundamentals help investors to digest information that contributes to GenoFocus' financial success or failures. It also enables traders to predict the movement of GenoFocus Stock. The fundamental analysis module provides a way to measure GenoFocus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GenoFocus stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

GenoFocus Company Net Asset Analysis

GenoFocus' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

 = 

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis

Current GenoFocus Net Asset

    
  118.52 B  
Most of GenoFocus' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GenoFocus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition

Based on the recorded statements, GenoFocus has a Net Asset of 118.52 B. This is much higher than that of the Chemicals sector and significantly higher than that of the Materials industry. The net asset for all Republic of Korea stocks is notably lower than that of the firm.

GenoFocus Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GenoFocus' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GenoFocus could also be used in its relative valuation, which is a method of valuing GenoFocus by comparing valuation metrics of similar companies.
GenoFocus is currently under evaluation in net asset category among its peers.

GenoFocus Fundamentals

About GenoFocus Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GenoFocus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GenoFocus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GenoFocus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with GenoFocus

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GenoFocus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GenoFocus will appreciate offsetting losses from the drop in the long position's value.

Moving against GenoFocus Stock

  0.74005380 Hyundai MotorPairCorr
  0.66005387 Hyundai MotorPairCorr
  0.64004020 Hyundai SteelPairCorr
  0.62051910 LG ChemicalsPairCorr
  0.61009830 Hanwha SolutionsPairCorr
The ability to find closely correlated positions to GenoFocus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GenoFocus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GenoFocus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GenoFocus to buy it.
The correlation of GenoFocus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GenoFocus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GenoFocus moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GenoFocus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in GenoFocus Stock

GenoFocus financial ratios help investors to determine whether GenoFocus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GenoFocus with respect to the benefits of owning GenoFocus security.